A detailed history of Ameriprise Financial Inc transactions in Biogen Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 1,150,486 shares of BIIB stock, worth $173 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,150,486
Previous 1,450,005 20.66%
Holding current value
$173 Million
Previous $336 Million 33.66%
% of portfolio
0.06%
Previous 0.09%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$189.07 - $236.8 $56.6 Million - $70.9 Million
-299,519 Reduced 20.66%
1,150,486 $223 Million
Q2 2024

Aug 14, 2024

BUY
$190.52 - $236.72 $124 Million - $154 Million
651,345 Added 81.55%
1,450,005 $336 Million
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $126 Million - $160 Million
596,173 Added 294.43%
798,660 $172 Million
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $3.53 Million - $4.25 Million
-15,878 Reduced 7.27%
202,487 $52.4 Million
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $4.97 Million - $5.61 Million
19,638 Added 9.88%
218,365 $56.1 Million
Q2 2023

Aug 14, 2023

SELL
$275.25 - $318.06 $3.33 Million - $3.85 Million
-12,113 Reduced 5.75%
198,727 $56.6 Million
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $22.3 Million - $25.4 Million
86,919 Added 70.14%
210,840 $58.6 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $949,174 - $1.15 Million
3,760 Added 3.13%
123,921 $34.3 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $113,114 - $155,975
-581 Reduced 0.48%
120,161 $32.2 Million
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $7.15 Million - $8.5 Million
-38,111 Reduced 23.99%
120,742 $24.5 Million
Q1 2022

May 16, 2022

SELL
$193.77 - $244.14 $99.2 Million - $125 Million
-512,072 Reduced 76.32%
158,853 $32.8 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $65 Million - $83.5 Million
290,289 Added 76.26%
670,925 $160 Million
Q3 2021

Nov 15, 2021

BUY
$282.99 - $369.05 $54.1 Million - $70.6 Million
191,227 Added 100.96%
380,636 $108 Million
Q2 2021

Aug 16, 2021

SELL
$259.0 - $414.71 $2.2 Million - $3.53 Million
-8,513 Reduced 4.3%
189,409 $65.6 Million
Q1 2021

May 17, 2021

BUY
$242.95 - $284.63 $24 Million - $28.1 Million
98,756 Added 99.59%
197,922 $55.4 Million
Q4 2020

Feb 12, 2021

SELL
$236.26 - $355.63 $6.56 Million - $9.88 Million
-27,783 Reduced 21.89%
99,166 $24.3 Million
Q3 2020

Nov 16, 2020

BUY
$264.77 - $305.71 $163,627 - $188,928
618 Added 0.49%
126,949 $36 Million
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $14.2 Million - $18.8 Million
-54,918 Reduced 30.3%
126,331 $33.7 Million
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $3.91 Million - $4.96 Million
-14,530 Reduced 7.42%
181,249 $57.3 Million
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $5.6 Million - $7.74 Million
-25,443 Reduced 11.5%
195,779 $58.1 Million
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $7.31 Million - $8.2 Million
-33,624 Reduced 13.19%
221,222 $51.5 Million
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $71.7 Million - $79 Million
-327,010 Reduced 56.2%
254,846 $59.2 Million
Q1 2019

May 15, 2019

SELL
$216.71 - $338.96 $350 Million - $548 Million
-1,615,629 Reduced 73.52%
581,856 $137 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $164 Million - $208 Million
-588,438 Reduced 21.12%
2,197,485 $661 Million
Q3 2018

Nov 14, 2018

BUY
$293.51 - $383.83 $2.47 Million - $3.23 Million
8,418 Added 0.3%
2,785,923 $1.06 Billion
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $44.2 Million - $52.7 Million
171,656 Added 6.59%
2,777,505 $806 Million
Q1 2018

May 15, 2018

SELL
$260.13 - $367.91 $415,427 - $587,552
-1,597 Reduced 0.06%
2,605,849 $714 Million
Q4 2017

Feb 12, 2018

BUY
$307.64 - $344.58 $91.7 Million - $103 Million
298,052 Added 12.91%
2,607,446 $831 Million
Q3 2017

Nov 07, 2017

BUY
$281.15 - $329.69 $649 Million - $761 Million
2,309,394
2,309,394 $723 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.